The evolving use of arsenic in pharmacotherapy of malignant disease

For more than 2,000 years, arsenic and its derivatives have shown medical utility. Owing to the toxicities and potential carcinogenicity of arsenicals, their popularity has fluctuated. The exact mechanism of action of therapeutic arsenic is not well characterized but likely to involve apoptosis, gen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of hematology 2013-06, Vol.92 (6), p.719-730
Hauptverfasser: Kritharis, Athena, Bradley, Thomas P., Budman, Daniel R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 730
container_issue 6
container_start_page 719
container_title Annals of hematology
container_volume 92
creator Kritharis, Athena
Bradley, Thomas P.
Budman, Daniel R.
description For more than 2,000 years, arsenic and its derivatives have shown medical utility. Owing to the toxicities and potential carcinogenicity of arsenicals, their popularity has fluctuated. The exact mechanism of action of therapeutic arsenic is not well characterized but likely to involve apoptosis, generation of reactive oxygen species, inhibition of intracellular transduction pathways, and cell functions. Arsenic trioxide has received approval for use in patients with relapsed acute promyelocytic leukemia for remission induction. Arsenic has additionally shown activity in a range of solid tumors, myelodysplastic syndrome, multiple myeloma, and in autoimmune diseases. The following is a review of the history of arsenic, its cellular metabolism, pharmacology, genetic basis of disposition, associated toxicities, and clinical efficacy.
doi_str_mv 10.1007/s00277-013-1707-3
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1357185552</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2984714861</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-58f72148f45eb6223adb9cb89c7d6b0aa60d0d92c0deb71f26884548af287e4d3</originalsourceid><addsrcrecordid>eNp1kMlOwzAQhi0EoqXwAFxQJM6G8ZLYOaKKTarEpZwtJ560qZoFu6nUt8dVCuLCXOYw_6L5CLll8MAA1GMA4EpRYIIyBYqKMzJlUnAKqZbnZAq5yGkaZ0KuQtgAMK4lvyQTLmQuOYgpmS_XmOC-2-7rdpUMAZOuSqwP2NZlUrdJv7a-sWW3W6O3_eF4bey2XrW23SWuDmgDXpOLym4D3pz2jHy-PC_nb3Tx8fo-f1rQUgq9o6muFGdSVzLFIuNcWFfkZaHzUrmsAGszcOByXoLDQrGKZ1rLVGpbca1QOjEj92Nu77uvAcPObLrBt7HSMJEqpuOnPKrYqCp9F4LHyvS-bqw_GAbmiM2M2EzEZo7YjIieu1PyUDTofh0_nKKAj4IQT-0K_Z_qf1O_AbWLdzE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1357185552</pqid></control><display><type>article</type><title>The evolving use of arsenic in pharmacotherapy of malignant disease</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kritharis, Athena ; Bradley, Thomas P. ; Budman, Daniel R.</creator><creatorcontrib>Kritharis, Athena ; Bradley, Thomas P. ; Budman, Daniel R.</creatorcontrib><description>For more than 2,000 years, arsenic and its derivatives have shown medical utility. Owing to the toxicities and potential carcinogenicity of arsenicals, their popularity has fluctuated. The exact mechanism of action of therapeutic arsenic is not well characterized but likely to involve apoptosis, generation of reactive oxygen species, inhibition of intracellular transduction pathways, and cell functions. Arsenic trioxide has received approval for use in patients with relapsed acute promyelocytic leukemia for remission induction. Arsenic has additionally shown activity in a range of solid tumors, myelodysplastic syndrome, multiple myeloma, and in autoimmune diseases. The following is a review of the history of arsenic, its cellular metabolism, pharmacology, genetic basis of disposition, associated toxicities, and clinical efficacy.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-013-1707-3</identifier><identifier>PMID: 23494203</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Antineoplastic Agents - adverse effects ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Arsenic Poisoning - diagnosis ; Arsenic Poisoning - etiology ; Arsenicals - administration &amp; dosage ; Arsenicals - adverse effects ; Arsenicals - pharmacology ; Arsenicals - therapeutic use ; Biotransformation - genetics ; Biotransformation - physiology ; Clinical Trials as Topic ; Diabetes Mellitus, Type 2 - chemically induced ; Gastrointestinal Diseases - chemically induced ; Gene Expression Regulation - drug effects ; Heart Diseases - chemically induced ; Hematology ; Humans ; Leukemia, Promyelocytic, Acute - drug therapy ; Leukocytosis - chemically induced ; Medicine ; Medicine &amp; Public Health ; Metabolic Networks and Pathways - drug effects ; Methyltransferases - genetics ; Methyltransferases - metabolism ; Neoplasms - chemically induced ; Neoplasms - drug therapy ; Oncology ; Oxides - adverse effects ; Oxides - therapeutic use ; Reactive Oxygen Species - metabolism ; Review Article ; Signal Transduction - drug effects ; Treatment Outcome</subject><ispartof>Annals of hematology, 2013-06, Vol.92 (6), p.719-730</ispartof><rights>Springer-Verlag Berlin Heidelberg 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-58f72148f45eb6223adb9cb89c7d6b0aa60d0d92c0deb71f26884548af287e4d3</citedby><cites>FETCH-LOGICAL-c438t-58f72148f45eb6223adb9cb89c7d6b0aa60d0d92c0deb71f26884548af287e4d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-013-1707-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-013-1707-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23494203$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kritharis, Athena</creatorcontrib><creatorcontrib>Bradley, Thomas P.</creatorcontrib><creatorcontrib>Budman, Daniel R.</creatorcontrib><title>The evolving use of arsenic in pharmacotherapy of malignant disease</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>For more than 2,000 years, arsenic and its derivatives have shown medical utility. Owing to the toxicities and potential carcinogenicity of arsenicals, their popularity has fluctuated. The exact mechanism of action of therapeutic arsenic is not well characterized but likely to involve apoptosis, generation of reactive oxygen species, inhibition of intracellular transduction pathways, and cell functions. Arsenic trioxide has received approval for use in patients with relapsed acute promyelocytic leukemia for remission induction. Arsenic has additionally shown activity in a range of solid tumors, myelodysplastic syndrome, multiple myeloma, and in autoimmune diseases. The following is a review of the history of arsenic, its cellular metabolism, pharmacology, genetic basis of disposition, associated toxicities, and clinical efficacy.</description><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Arsenic Poisoning - diagnosis</subject><subject>Arsenic Poisoning - etiology</subject><subject>Arsenicals - administration &amp; dosage</subject><subject>Arsenicals - adverse effects</subject><subject>Arsenicals - pharmacology</subject><subject>Arsenicals - therapeutic use</subject><subject>Biotransformation - genetics</subject><subject>Biotransformation - physiology</subject><subject>Clinical Trials as Topic</subject><subject>Diabetes Mellitus, Type 2 - chemically induced</subject><subject>Gastrointestinal Diseases - chemically induced</subject><subject>Gene Expression Regulation - drug effects</subject><subject>Heart Diseases - chemically induced</subject><subject>Hematology</subject><subject>Humans</subject><subject>Leukemia, Promyelocytic, Acute - drug therapy</subject><subject>Leukocytosis - chemically induced</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Metabolic Networks and Pathways - drug effects</subject><subject>Methyltransferases - genetics</subject><subject>Methyltransferases - metabolism</subject><subject>Neoplasms - chemically induced</subject><subject>Neoplasms - drug therapy</subject><subject>Oncology</subject><subject>Oxides - adverse effects</subject><subject>Oxides - therapeutic use</subject><subject>Reactive Oxygen Species - metabolism</subject><subject>Review Article</subject><subject>Signal Transduction - drug effects</subject><subject>Treatment Outcome</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kMlOwzAQhi0EoqXwAFxQJM6G8ZLYOaKKTarEpZwtJ560qZoFu6nUt8dVCuLCXOYw_6L5CLll8MAA1GMA4EpRYIIyBYqKMzJlUnAKqZbnZAq5yGkaZ0KuQtgAMK4lvyQTLmQuOYgpmS_XmOC-2-7rdpUMAZOuSqwP2NZlUrdJv7a-sWW3W6O3_eF4bey2XrW23SWuDmgDXpOLym4D3pz2jHy-PC_nb3Tx8fo-f1rQUgq9o6muFGdSVzLFIuNcWFfkZaHzUrmsAGszcOByXoLDQrGKZ1rLVGpbca1QOjEj92Nu77uvAcPObLrBt7HSMJEqpuOnPKrYqCp9F4LHyvS-bqw_GAbmiM2M2EzEZo7YjIieu1PyUDTofh0_nKKAj4IQT-0K_Z_qf1O_AbWLdzE</recordid><startdate>20130601</startdate><enddate>20130601</enddate><creator>Kritharis, Athena</creator><creator>Bradley, Thomas P.</creator><creator>Budman, Daniel R.</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20130601</creationdate><title>The evolving use of arsenic in pharmacotherapy of malignant disease</title><author>Kritharis, Athena ; Bradley, Thomas P. ; Budman, Daniel R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-58f72148f45eb6223adb9cb89c7d6b0aa60d0d92c0deb71f26884548af287e4d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Arsenic Poisoning - diagnosis</topic><topic>Arsenic Poisoning - etiology</topic><topic>Arsenicals - administration &amp; dosage</topic><topic>Arsenicals - adverse effects</topic><topic>Arsenicals - pharmacology</topic><topic>Arsenicals - therapeutic use</topic><topic>Biotransformation - genetics</topic><topic>Biotransformation - physiology</topic><topic>Clinical Trials as Topic</topic><topic>Diabetes Mellitus, Type 2 - chemically induced</topic><topic>Gastrointestinal Diseases - chemically induced</topic><topic>Gene Expression Regulation - drug effects</topic><topic>Heart Diseases - chemically induced</topic><topic>Hematology</topic><topic>Humans</topic><topic>Leukemia, Promyelocytic, Acute - drug therapy</topic><topic>Leukocytosis - chemically induced</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Metabolic Networks and Pathways - drug effects</topic><topic>Methyltransferases - genetics</topic><topic>Methyltransferases - metabolism</topic><topic>Neoplasms - chemically induced</topic><topic>Neoplasms - drug therapy</topic><topic>Oncology</topic><topic>Oxides - adverse effects</topic><topic>Oxides - therapeutic use</topic><topic>Reactive Oxygen Species - metabolism</topic><topic>Review Article</topic><topic>Signal Transduction - drug effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kritharis, Athena</creatorcontrib><creatorcontrib>Bradley, Thomas P.</creatorcontrib><creatorcontrib>Budman, Daniel R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kritharis, Athena</au><au>Bradley, Thomas P.</au><au>Budman, Daniel R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The evolving use of arsenic in pharmacotherapy of malignant disease</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2013-06-01</date><risdate>2013</risdate><volume>92</volume><issue>6</issue><spage>719</spage><epage>730</epage><pages>719-730</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>For more than 2,000 years, arsenic and its derivatives have shown medical utility. Owing to the toxicities and potential carcinogenicity of arsenicals, their popularity has fluctuated. The exact mechanism of action of therapeutic arsenic is not well characterized but likely to involve apoptosis, generation of reactive oxygen species, inhibition of intracellular transduction pathways, and cell functions. Arsenic trioxide has received approval for use in patients with relapsed acute promyelocytic leukemia for remission induction. Arsenic has additionally shown activity in a range of solid tumors, myelodysplastic syndrome, multiple myeloma, and in autoimmune diseases. The following is a review of the history of arsenic, its cellular metabolism, pharmacology, genetic basis of disposition, associated toxicities, and clinical efficacy.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>23494203</pmid><doi>10.1007/s00277-013-1707-3</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0939-5555
ispartof Annals of hematology, 2013-06, Vol.92 (6), p.719-730
issn 0939-5555
1432-0584
language eng
recordid cdi_proquest_journals_1357185552
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Antineoplastic Agents - adverse effects
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Arsenic Poisoning - diagnosis
Arsenic Poisoning - etiology
Arsenicals - administration & dosage
Arsenicals - adverse effects
Arsenicals - pharmacology
Arsenicals - therapeutic use
Biotransformation - genetics
Biotransformation - physiology
Clinical Trials as Topic
Diabetes Mellitus, Type 2 - chemically induced
Gastrointestinal Diseases - chemically induced
Gene Expression Regulation - drug effects
Heart Diseases - chemically induced
Hematology
Humans
Leukemia, Promyelocytic, Acute - drug therapy
Leukocytosis - chemically induced
Medicine
Medicine & Public Health
Metabolic Networks and Pathways - drug effects
Methyltransferases - genetics
Methyltransferases - metabolism
Neoplasms - chemically induced
Neoplasms - drug therapy
Oncology
Oxides - adverse effects
Oxides - therapeutic use
Reactive Oxygen Species - metabolism
Review Article
Signal Transduction - drug effects
Treatment Outcome
title The evolving use of arsenic in pharmacotherapy of malignant disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T08%3A49%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20evolving%20use%20of%20arsenic%20in%20pharmacotherapy%20of%20malignant%20disease&rft.jtitle=Annals%20of%20hematology&rft.au=Kritharis,%20Athena&rft.date=2013-06-01&rft.volume=92&rft.issue=6&rft.spage=719&rft.epage=730&rft.pages=719-730&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-013-1707-3&rft_dat=%3Cproquest_cross%3E2984714861%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1357185552&rft_id=info:pmid/23494203&rfr_iscdi=true